MIV-711 phase IIa osteoarthritis study data presented as a late breaking poster at the Annual Meeting of the American College for Rheumatology
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that data from the initial phase IIa study of MIV-711 in patients with moderate knee osteoarthritis were presented as a late-breaking poster at the 2017 annual meeting of the American College for Rheumatology (ACR), which took place from November 3-8 in San Diego, USA. The presentation, entitled “MIV-711, a Novel Cathepsin K Inhibitor Demonstrates Evidence of Osteoarthritis Structure Modification: Results from a 6 Month Randomised Double-Blind Placebo-Controlled Phase IIa Trial”, was made by Professor Philip Conaghan,